×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TRVI – trevi therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TRVI
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/19
03:53 pm
trvi
Trevi Therapeutics (TRVI) had its price target lowered by JonesTrading from $25.00 to $24.00. They now have a "buy" rating on the stock.
Low
Report
Trevi Therapeutics (TRVI) had its price target lowered by JonesTrading from $25.00 to $24.00. They now have a "buy" rating on the stock.
3/18
06:48 pm
trvi
Trevi Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Trevi Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
3/18
11:48 am
trvi
Trevi Therapeutics (TRVI) had its price target lowered by Morgan Stanley from $19.00 to $18.00. They now have an "overweight" rating on the stock.
Low
Report
Trevi Therapeutics (TRVI) had its price target lowered by Morgan Stanley from $19.00 to $18.00. They now have an "overweight" rating on the stock.
3/18
08:40 am
trvi
Trevi Therapeutics (TRVI) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $19.00 price target on the stock.
Medium
Report
Trevi Therapeutics (TRVI) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $19.00 price target on the stock.
3/18
08:03 am
trvi
Trevi Therapeutics (TRVI) had its price target raised by Needham & Company LLC from $22.00 to $24.00. They now have a "buy" rating on the stock.
Medium
Report
Trevi Therapeutics (TRVI) had its price target raised by Needham & Company LLC from $22.00 to $24.00. They now have a "buy" rating on the stock.
3/17
11:02 pm
trvi
Trevi Therapeutics Inc (TRVI) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
Medium
Report
Trevi Therapeutics Inc (TRVI) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
3/17
04:43 pm
trvi
Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates [Yahoo! Finance]
Low
Report
Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates [Yahoo! Finance]
3/17
04:05 pm
trvi
Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates
Medium
Report
Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/17
04:09 pm
trvi
Form 10-K Trevi Therapeutics, Inc. For: Dec 31
Medium
Report
Form 10-K Trevi Therapeutics, Inc. For: Dec 31
3/17
04:07 pm
trvi
Form 8-K Trevi Therapeutics, Inc. For: Mar 17
Medium
Report
Form 8-K Trevi Therapeutics, Inc. For: Mar 17
3/9
04:35 pm
trvi
Form 8-K Trevi Therapeutics, Inc. For: Mar 09
Low
Report
Form 8-K Trevi Therapeutics, Inc. For: Mar 09
2/20
04:17 pm
trvi
Form 4 Trevi Therapeutics, Inc. For: Feb 19 Filed by: Galletta Christopher
Medium
Report
Form 4 Trevi Therapeutics, Inc. For: Feb 19 Filed by: Galletta Christopher
2/20
04:17 pm
trvi
Form 4 Trevi Therapeutics, Inc. For: Feb 19 Filed by: Cassella James V
Medium
Report
Form 4 Trevi Therapeutics, Inc. For: Feb 19 Filed by: Cassella James V
2/20
04:16 pm
trvi
Form 4 Trevi Therapeutics, Inc. For: Feb 19 Filed by: Simon Farrell
Medium
Report
Form 4 Trevi Therapeutics, Inc. For: Feb 19 Filed by: Simon Farrell
2/20
04:16 pm
trvi
Form 4 Trevi Therapeutics, Inc. For: Feb 19 Filed by: SCIASCIA THOMAS
Medium
Report
Form 4 Trevi Therapeutics, Inc. For: Feb 19 Filed by: SCIASCIA THOMAS
2/20
04:16 pm
trvi
Form 4 Trevi Therapeutics, Inc. For: Feb 19 Filed by: GOOD JENNIFER L
Medium
Report
Form 4 Trevi Therapeutics, Inc. For: Feb 19 Filed by: GOOD JENNIFER L
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/31
Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.50 price target on the stock.
67.9%
3/16 TREVI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND YEAR END 2019 FINANCIAL RESULTS AND CORPORATE UPDATE 48.3%
6/18 Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference 12.7%
5/13 Form 3 Trevi Therapeutics, Inc. For: May 07 Filed by: OSHEA WILLIAM J 11.5%
3/16 Trevi Therapeutics up 57% on advancement of key programs [Seeking Alpha] 10.3%
4/13 Form 4 Trevi Therapeutics, Inc. For: Apr 03 Filed by: Behbahani Ali 9.9%
2/25 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 8.6%
1/15 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 7.9%
11/14 Form 8-K Trevi Therapeutics, Inc. For: Nov 14 7.9%
8/21 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 7.6%
3/16 TREVI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND YEAR END 2019 FINANCIAL RESULTS AND CORPORATE UPDATE 48.3%
6/18 Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference 12.7%
5/13 Form 3 Trevi Therapeutics, Inc. For: May 07 Filed by: OSHEA WILLIAM J 11.5%
3/16 Trevi Therapeutics up 57% on advancement of key programs [Seeking Alpha] 10.3%
4/13 Form 4 Trevi Therapeutics, Inc. For: Apr 03 Filed by: Behbahani Ali 9.9%
2/25 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 8.6%
1/15 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 7.9%
11/14 Form 8-K Trevi Therapeutics, Inc. For: Nov 14 7.9%
8/21 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 7.6%
TOP News Decliners
5/7
Form S-1/A Trevi Therapeutics, Inc.
-16.9%
10/10 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -9.8%
3/11 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -8.8%
8/12 Trevi Therapeutics Announces Second Quarter 2019 Financial Results and Recent Business Developments -7.1%
1/31 Form SC 13G Trevi Therapeutics, Inc. Filed by: Lundbeckfond Invest A/S -6.2%
2/13 Form SC 13G Trevi Therapeutics, Inc. Filed by: TPG Group Holdings (SBS) Advisors, Inc. -6.2%
9/19 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -4.9%
2/20 Trevi Therapeutics to Present at SVB Leerink Healthcare Conference -4.0%
7/2 Form 8-K Trevi Therapeutics, Inc. For: Jun 28 -4.0%
6/25 Trevi Therapeutics (TRVI) Investor Presentation - Slideshow [Seeking Alpha] -3.8%
10/10 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -9.8%
3/11 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -8.8%
8/12 Trevi Therapeutics Announces Second Quarter 2019 Financial Results and Recent Business Developments -7.1%
1/31 Form SC 13G Trevi Therapeutics, Inc. Filed by: Lundbeckfond Invest A/S -6.2%
2/13 Form SC 13G Trevi Therapeutics, Inc. Filed by: TPG Group Holdings (SBS) Advisors, Inc. -6.2%
9/19 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -4.9%
2/20 Trevi Therapeutics to Present at SVB Leerink Healthcare Conference -4.0%
7/2 Form 8-K Trevi Therapeutics, Inc. For: Jun 28 -4.0%
6/25 Trevi Therapeutics (TRVI) Investor Presentation - Slideshow [Seeking Alpha] -3.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: